Form 4: Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Reports Stock Transactions
SEC Form 4 Filing
Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reported the vesting of restricted stock units and the sale of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On February 8, 2025, Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, had 1,727 restricted stock units (RSUs) vest.
- These RSUs represent a contingent right to receive one share of Neurocrine Biosciences' common stock each.
- The RSUs were granted on February 8, 2021, and vested in four equal installments annually.
- On February 10, 2025, Lippoldt sold 911 shares of common stock at a weighted average price of $118.2514 per share.
- The sales were executed under a Rule 10b5-1 trading plan adopted on June 10, 2021.
- Following these transactions, Lippoldt beneficially owns 41,679 shares of Neurocrine Biosciences common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies. The use of a 10b5-1 trading plan suggests a pre-planned and compliant approach to selling company stock.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
- Rule 10b5-1 trading plans are a standard practice among corporate executives to avoid accusations of insider trading.
- The reported transactions are typical for executives at publicly traded companies like Neurocrine Biosciences; similar filings are regularly seen from executives at companies such as Amgen, Biogen, and Vertex Pharmaceuticals.
Stakeholder Impact
- The stock sale may have a minor, temporary impact on the stock price.
- The vesting of RSUs is part of the executive's compensation package, impacting shareholder equity.
Key Dates
| Date | Description |
|---|---|
| 2021/02/08 | RSU grant date |
| 2021/06/10 | Rule 10b5-1 trading plan adoption date |
| 2022/02/08 | First RSU vesting date (1,727 shares) |
| 2023/02/08 | Second RSU vesting date (1,727 shares) |
| 2024/02/08 | Third RSU vesting date (1,727 shares) |
| 2025/02/08 | Fourth RSU vesting date (1,727 shares) |
| 2025/02/10 | Common stock sale date |
Keywords
Neurocrine Biosciences, NBIX, Darin Lippoldt, Form 4, Stock Sale, Restricted Stock Units, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.